우홍균 교수
Hong-Gyun Wu
서울대학교 방사선종양학과 · 의학
연구실 소개
우홍균 교수의 연구실은 난소암, 갑상선암, 흉부암 및 두경부암을 중심으로 암의 분자표적치료와 면역치료의 예측 마커를 규명하는 데 주력하고 있습니다. 특히 PD-L1 발현의 동적 변화와 화학요법 이후의 면역조절 메커니즘을 분석하여 치료 반응을 예측하고자 하며, 방사선 치료의 정밀도 향상과 부작용 최소화를 위한 최신 방사선 옹호 기술(예: IMRT, VMAT, MRI 기반 방사선 치료)의 계획 품질 평가도 수행하고 있습니다. 이와 더불어, 희귀암인 갑상선암의 아구성형 및 분화형 암의 치료 전략 수립에도 기여하고 있습니다.
연구 현황
연구 성과 추이
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
주요 논문
15// Chan-Young Ock 1, * , Sehui Kim 2, * , Bhumsuk Keam 1, 3 , Miso Kim 1 , Tae Min Kim 1, 3 , Jin-Ho Kim 4 , Yoon Kyung Jeon 2 , Ju-Seog Lee 5 , Seong Keun Kwon 6 , J. Hun Hah 6 , Tack-Kyun Kwon 6 , Dong-Wan Kim 1, 3 , Hong-Gyun Wu 4 , Myung-Whun Sung 6 , Dae Seog Heo 1, 3 1 Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea 2 Department of Pathology, Seoul National University Hospital Seoul, Korea 3 Cancer Research Institute, Seoul National University College of M
Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment. Paired HNSCC tissues prior to and after cisplatin-based treatment were evaluated to determine PD-L1 protein expression by immunohistochemistry. Among the 35 HNSCC patient samples, PD-L1 expression status changed after treatment in 37.1% (13/35) of samples.
The choice of treatment of ATC and PDTC could be modified according to resectability and lymphatic invasion of the cancer.
BACKGROUND: To compare the acute gastrointestinal (GI) and genitourinary (GU) toxicity profiles between intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in rectal cancer patients treated with neoadjuvant chemoradiation (NCRT) using meta-analysis and pooled-analysis from published articles. METHODS: Literature search was performed in PubMed and EMBASE from inception to March 2017. The odd ratios (ORs) were calculated and random effects model was used fo
The aim of this study was to compare the plan quality of magnetic-resonance image-based intensity modulated radiation therapy (MRI-based-IMRT) with the MRIdian Linac system to that of volumetric modulated arc therapy (VMAT) with the TrueBeam STx system for lung stereotactic ablative radiotherapy (SABR). A total of 22 patients with tumors located in the lower lobe were retrospectively selected for the study. For each patient, both the MRI-based-IMRT and VMAT plans were generated using an identica
To screen the differentially expressed microRNAs related to radio-resistance, we compared the microRNA profiles of lung cancer cells with different responses to ionizing radiation (IR). Of 328 microRNAs in microarray, 27 microRNAs were differentially expressed in NCI-H460 (H460) and NCI-H1299 (H1299) cells. Among them, let-7g was down-regulated in radio-resistant H1299 cells, and the level of let-7g was higher in radio- sensitive cells like Caski, H460, and ME180 in qRT-PCR analysis than in radi
PURPOSE: This study evaluates the long-term results of definitive radiotherapy (RT) for early glottic cancer. Clinical and treatment factors related to local control and patterns of failure are analyzed. MATERIALS AND METHODS: We retrospectively reviewed 222 patients with T1-2N0 squamous cell carcinoma of the glottic larynx treated with definitive RT from 1981 to 2010. None of the patients received elective nodal RT or combined chemotherapy. The median total RT dose was 66 Gy. The daily fraction
대표 연구 분야
우홍균 교수의 연구를 Nubint에서 더 깊이 살펴보세요
이 연구실의 논문을 앱에서 열어 AI와 함께 읽고, 핵심을 요약하고, 내 글에 인용하세요.